Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy

(1059) Article views

Authors: Maristella D’Uva, Pierpaolo Di Micco, Ida Strina, Antonio Ranieri, Carlo Alviggi, et al

Published Date October 2008 , Volume 2008:2(4)

Maristella D’Uva¹, Pierpaolo Di Micco², Ida Strina¹, Antonio Ranieri¹, Carlo Alviggi¹, Antonio Mollo¹, Francesca Fabozzi¹, Lucia Cacciapuoti¹, Maria Teresa Scotto di Frega¹, Mariateresa Iannuzzo², Giuseppe De Placido¹

¹Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Area Funzionale di Medicina della Riproduzione ed Endoscopia Ginecologica, Università degli Studi di Napoli Federico II, via Pansini 5 Building 9, 80131, Naples, Italy; ²Internal Medicine Division, Fatebenefratelli Hospital of Naples, Naples, Italy

Background: Recurrent fetal loss (RPL) is one of the most common cause of sterility. Several studies identified thrombophilia as the principal cause of recurrent pregnancy loss. However, reported studies often do not evaluate other causes of miscarriages in their inclusion and exclusion criteria. So the aim of our study was to investigate the role of inherited thrombophilia in patients with RPL and without other causes of RPL.

Patients and methods: Patients with 2 or more first trimester abortion or with 1 or more late pregnancy loss were considered for this study. In order to evaluate the causes of RPL we looked for chromosomal, endocrine, chronic inflammatory, and infectious alterations. 90 patients affected by unexplained RPL were enrolled and tested for hemostatic alterations. These women were tested for inherited and/or acquired thrombophilia by MTHFR C677T gene polymorphism, factor V Leiden gene polymorphism, PTHRA20210G gene polymorphism, protein S deficiency, protein C deficiency, antithrombin III deficiency, lupus anticoagulant, and anticardiolipin antibodies Ig G and Ig M.

Results: Acquired and/or inherited thrombophilia are strongly associated with RPL when other common causes of miscarriage were excluded. 78% of tested women showed hemostatic abnormalities. Several women with combined thrombophilic defects were also identified by our data.

Conclusion: After a thorough evaluation of other causes of miscarriage women affected by RPL should be tested for thrombophilia. Our data demonstrated 78% of women with one or combined thrombophilic conditions. Differences with previous studies should be related to difference in the inclusion and exclusion criteria and ethnic background. Because these patients often also show a hypercoagulable state, it an antithrombotic treatment before and during pregnancy may improve their clinical outcome (ie, secondary prevention of miscarriage and primary thromboprophylaxis).

Keywords: recurrent pregnancy loss, late pregnancy loss, thrombophilia, hypercoagulable state, hyperhomocysteinemia, factor V Leiden, prothrombin, antithrombotic drugs

Other articles by Dr Pierpaolo Di Micco